Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): A phase II study in colorectal cancer patients with non-resectable liver metastases

Abstract

Purpose: To assess the rate of R0 resection of liver metastases achieved after chemotherapy with FOLFIRINOX. Patients and methods: Patients with histologically proven primary colorectal cancer and bidimensionally measurable liver metastasis, not fully resectable based on technical inability to achieve R0 resection, but potentially resectable after tumor reduction, were given FOLFIRINOX: oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2, bolus fluorouracil 400 mg/m2 and fluorouracil 46-h continuous IV infusion 2,400 mg/m2, every 2 weeks for a maximum of 12 cycles. Results: Thirty-four patients were enrolled. Response rate before surgery was 70.6% (95%CI: 52.5-84.9). Twenty-eight patients (82.4%) underwent hepatic resection and nine achieved R0 resection [26.5% (95% CI: 12.9-44.4%)]. The rate of clinical complete remission after surgery was 79.4%. Two-year overall survival was 83%. The most frequent grade 3 or 4 toxicities were neutropenia (64.8%), diarrhea (29.4%), fatigue (23.5%), abdominal cramps (14.7%), neuropathy and nausea (11.8% each), and AST/ALT elevation (14.7/11.8%). Only one patient experienced febrile neutropenia, four patients withdrew due to toxicity and no toxic death was observed. Conclusion: FOLFIRINOX, with an acceptable toxicity profile, shows a high response rate in liver metastases from colorectal cancer. The rate of hepatic resection in patients initially not resectable, is attractive and warrants further assessment of this regimen in randomized studies compared to standard regimens. © 2007 Springer-Verlag.